Published in BMC Med on July 22, 2016
Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology (2005) 29.57
Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med (1996) 16.98
Inflammatory bowel disease. N Engl J Med (2009) 8.62
The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut (2006) 8.08
Pneumococcal vaccination decreases atherosclerotic lesion formation: molecular mimicry between Streptococcus pneumoniae and oxidized LDL. Nat Med (2003) 4.47
Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. J Clin Invest (2009) 2.75
Immunization of low density lipoprotein (LDL) receptor-deficient rabbits with homologous malondialdehyde-modified LDL reduces atherogenesis. Proc Natl Acad Sci U S A (1995) 2.44
NAFLD, NASH and liver cancer. Nat Rev Gastroenterol Hepatol (2013) 2.20
Plasma metabolomic profile in nonalcoholic fatty liver disease. Metabolism (2010) 1.77
B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res (2011) 1.67
Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity? Hepatology (2002) 1.66
Lipid-Induced Signaling Causes Release of Inflammatory Extracellular Vesicles From Hepatocytes. Gastroenterology (2016) 1.65
Immunoglobulin M is required for protection against atherosclerosis in low-density lipoprotein receptor-deficient mice. Circulation (2009) 1.61
Relationship of IgG and IgM autoantibodies to oxidized low density lipoprotein with coronary artery disease and cardiovascular events. J Lipid Res (2006) 1.61
Immunization of LDL receptor-deficient mice with homologous malondialdehyde-modified and native LDL reduces progression of atherosclerosis by mechanisms other than induction of high titers of antibodies to oxidative neoepitopes. Arterioscler Thromb Vasc Biol (1998) 1.57
Human hepatic stellate cells show features of antigen-presenting cells and stimulate lymphocyte proliferation. Hepatology (2003) 1.57
NAFLD: a multisystem disease. J Hepatol (2015) 1.51
Association between reactive oxygen species and disease activity in chronic hepatitis C. Free Radic Biol Med (1996) 1.24
Oxidized low-density lipoproteins bind to the scavenger receptor, CD36, of hepatic stellate cells and stimulate extracellular matrix synthesis. Hepatology (2001) 1.19
Immune response towards lipid peroxidation products as a predictor of progression of non-alcoholic fatty liver disease to advanced fibrosis. Gut (2005) 1.19
Specific immunization strategies against oxidized low-density lipoprotein: a novel way to reduce nonalcoholic steatohepatitis in mice. Hepatology (2012) 1.13
Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study. J Lipid Res (2011) 1.09
Circulating microparticles as disease-specific biomarkers of severity of inflammation in patients with hepatitis C or nonalcoholic steatohepatitis. Gastroenterology (2012) 1.06
Natural IgM antibodies against oxidation-specific epitopes. J Clin Immunol (2010) 1.04
Current efforts and trends in the treatment of NASH. J Hepatol (2015) 1.02
Immunoglobulins and IgG subclasses in patients with inflammatory bowel disease. Hepatogastroenterology (1999) 1.00
Serum immunoglobulins predict the extent of hepatic fibrosis in patients with chronic hepatitis C virus infection. J Viral Hepat (2004) 0.98
Alterations in serum immunoglobulin G subclasses in patients with ulcerative colitis and Crohn's disease. Gastroenterology (1989) 0.96
Lipotoxic lethal and sublethal stress signaling in hepatocytes: relevance to NASH pathogenesis. J Lipid Res (2016) 0.95
Peptide mimotopes of malondialdehyde epitopes for clinical applications in cardiovascular disease. J Lipid Res (2012) 0.93
Immune-modulation by polyclonal IgM treatment reduces atherosclerosis in hypercholesterolemic apoE-/- mice. Atherosclerosis (2011) 0.93
Serum immunoglobulins (IgG, IgA, IgM) in chronic hepatitis C. A comparison with non-cirrhotic alcoholic liver disease. Hepatogastroenterology (2003) 0.92
Non-alcoholic steatohepatitis: the role of oxidized low-density lipoproteins. J Hepatol (2012) 0.91
Serum immunoglobulin levels predict fibrosis in patients with non-alcoholic fatty liver disease. J Hepatol (2014) 0.90
Combination of oxidative stress and steatosis is a risk factor for fibrosis in alcohol-drinking patients with chronic hepatitis C. Am J Gastroenterol (2008) 0.90
Antiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipids. Gut (2001) 0.89
Plasma levels of asymmetric dimethylarginine in patients with biopsy-proven nonalcoholic fatty liver disease. Metabolism (2010) 0.89
Circulating microparticles carry oxidation-specific epitopes and are recognized by natural IgM antibodies. J Lipid Res (2014) 0.87
Microparticles: Modulators and biomarkers of liver disease. J Hepatol (2012) 0.86
Frequency and risk factors of low immunoglobulin levels in patients with inflammatory bowel disease. Gastroenterol Rep (Oxf) (2015) 0.82
Serum immunoglobulin a concentration is an independent predictor of liver fibrosis in nonalcoholic steatohepatitis before the cirrhotic stage. Dig Dis Sci (2011) 0.79
Serum immunoglobulin A concentration is a reliable biomarker for liver fibrosis in non-alcoholic fatty liver disease. World J Gastroenterol (2014) 0.78
Sialic Acid-Binding Immunoglobulin-like Lectin G Promotes Atherosclerosis and Liver Inflammation by Suppressing the Protective Functions of B-1 Cells. Cell Rep (2016) 0.77
Pancreatitis-associated protein has no additional value as a marker of disease activity in a real-life cohort of IBD patients. Eur J Gastroenterol Hepatol (2014) 0.77
[Evaluation of serum IgG, IgA and IgM levels as indicators of hepatic fibrosis in patients with chronic hepatitis C infection]. Mikrobiyol Bul (2011) 0.76